Immunoregulatory potential of exogenous Schistosoma mansoni soluble egg antigen in a model of experimental schistosomiasis--I. Regulation of granuloma formation in vivo.
This study was undertaken to assess the optimum conditions required to reduce the vigorous host granulomatous reaction around Schistosoma mansoni eggs. Soluble schistosomal egg antigen (SEA) at a concentration of 10 or 100 micrograms protein was administered i.p. or i.v. into unprimed C57BL/6 mice. SEA was injected either alone or in combination with cyclophosphamide (CY) 100 or 50 mg/kg via i.p. route. Seven or 14 days later viable eggs of S. mansoni were injected via the tail vein into treated groups and untreated normal controls. Mice were sacrificed 8, 16 and 24 days after the injection of eggs. The lungs were removed for histopathological study, measurement of granuloma diameter and phenotypic analysis of granuloma intralesional T-cell subsets. Compared to untreated controls, the lower concentration of SEA (10 micrograms) administered by the i.v. route 7 days before egg injection, induced a significant reduction in granuloma diameter 16 days after egg injection than that by the i.p. route or at a higher SEA concentration (100 micrograms). Compared to untreated controls, the higher dose of CY (100 mg/kg), given i.p. alone or in combination with 10 micrograms SEA by the i.v. or i.p. route, induced a significant reduction in granuloma diameter, while 50 mg/kg CY did not cause any reduction. The reduction in granuloma diameter by i.v. administration of low SEA concentration alone or in combination with CY IP, was associated with a decrease in the granuloma intralesional L3T4+/Lyt2+ ratio. The decrease in the ratio was due to an increase in Lyt2+ cells. The results suggest that the use of low dose SEA by the i.v. route alone or combined with an immunosuppressive drug ameliorates pathological changes concurrent with S. mansoni infection.
Botros
S S
SS
Pharmacology Department, Theodor Bilharz Institute, Guiza, Egypt.
Hassanein
H I
HI
Hassan
S I
SI
Akl
M M
MM
Sakr
S S
SS
Shaker
Z A
ZA
Hafez
G L
GL
el Ghorab
N M
NM
Dean
D A
DA
D000818:Animals; D000947:Antigens, Helminth / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D006099:Granuloma / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D015801:Helminth Proteins; D006790:Host-Parasite Interactions; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008174:Lung Diseases, Parasitic / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008810:Mice, Inbred C57BL; D012550:Schistosoma mansoni / Q000276:immunology*; D012555:Schistosomiasis mansoni / Q000276:immunology* / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000473:pathology
D000947:Antigens, Helminth; D015801:Helminth Proteins; C055560:p40 egg antigen, Schistosoma; D003520:Cyclophosphamide